Company Growth (employees)
CytomX Therapeutics was founded in 2008 and is headquartered in South San Francisco, US
CytomX Therapeutics Office Locations
CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
100 343 Oyster Point Blvd
CytomX Therapeutics Data and Metrics
CytomX Therapeutics Financial Metrics
CytomX Therapeutics's revenue was reported to be $11.2 m in Q1, 2017
USD
Revenue (Q1, 2017) | 11.2 m |
Net income (Q1, 2017) | (8.3 m) |
EBIT (Q1, 2017) | (8.6 m) |
Market capitalization (22-Aug-2017) | 542.9 m |
Cash (31-Dec-2016) | 104.6 m |
CytomX Therapeutics's current market capitalization is $542.9 m.
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Revenue | 7.7 m | 15 m |
Revenue growth, % | 95% | |
EBIT | (33.2 m) | (59.6 m) |
EBIT margin, % | (431%) | (396%) |
Pre tax profit | (35.4 m) | (58.9 m) |
Net Income | (35.4 m) | (58.9 m) |
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|
Revenue | 1.9 m | 1.8 m | 2.5 m | 2.8 m | 11.2 m |
R&D expense | 9.2 m | 13.4 m | 12.7 m | 13.3 m | 14.6 m |
General and administrative expense | 4.1 m | 5 m | 4.6 m | 5 m | 5.7 m |
Operating expense total | 13.2 m | 18.4 m | 17.4 m | 18.4 m | 20.3 m |
EBIT | (11.3 m) | (16.2 m) | (14.3 m) | (14.9 m) | (8.6 m) |
EBIT margin, % | (581%) | (908%) | (562%) | (527%) | (77%) |
Interest expense | 718 k | 353 k | 465 k | 482 k | 206 k |
Interest income | 407 k | 490 k | 660 k | 692 k | 442 k |
Pre tax profit | (11.9 m) | (16 m) | (14.2 m) | (14.7 m) | |
Income tax expense | 3 k | 3 k | 3 k | 1 k | 1 k |
Net Income | (11.9 m) | (16 m) | (14.2 m) | (14.7 m) | (8.3 m) |
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 59.8 m | 104.6 m |
Accounts Receivable | 744 k | 2.2 m |
Inventories | 2.3 m | 3.9 m |
Current Assets | 189.8 m | 188.1 m |
PP&E | 3.5 m | 4.4 m |
Goodwill | 949 k | 949 k |
Total Assets | 197.2 m | 199.1 m |
Accounts Payable | 4.7 m | 6.6 m |
Current Liabilities | 15.7 m | 35.8 m |
Total Liabilities | 120.6 m | |
Additional Paid-in Capital | 243.7 m | 254.9 m |
Retained Earnings | (117.5 m) | (176.4 m) |
Total Equity | 126.1 m | 78.5 m |
Financial Leverage | 1.6 x | 2.5 x |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (35.4 m) | (58.9 m) |
Depreciation and Amortization | 1.2 m | 1.7 m |
Accounts Receivable | 1.1 m | (1.8 m) |
Accounts Payable | 2.9 m | 1.8 m |
Cash From Operating Activities | (27.4 m) | (2 m) |
Purchases of PP&E | (1.6 m) | (2.2 m) |
Cash From Investing Activities | (130.6 m) | 45.9 m |
Cash From Financing Activities | 153.4 m | 996 k |
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|
Net Income | (11.9 m) | (16 m) | (14.2 m) | (14.7 m) | (8.3 m) |
Accounts Receivable | 406 k | 316 k | 285 k | 240 k | 213 k |
Accounts Payable | 2.7 m | 5 m | 1.4 m | 517 k | 3.7 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 143.3 k |
